Other OTC - Delayed Quote USD

Igene Biotechnology, Inc. (IGNE)

0.0000 0.0000 (0.00%)
At close: March 21 at 3:20 PM EDT
Loading Chart for IGNE
DELL
  • Previous Close 0.0000
  • Open 0.0000
  • Bid --
  • Ask --
  • Day's Range 0.0000 - 0.0000
  • 52 Week Range 0.0000 - 0.0000
  • Volume 500
  • Avg. Volume 0
  • Market Cap (intraday) 109,578
  • Beta (5Y Monthly) -21.93
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.

www.igene.com

18

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: IGNE

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IGNE
90.00%
S&P 500
4.14%

1-Year Return

IGNE
90.00%
S&P 500
19.55%

3-Year Return

IGNE
99.89%
S&P 500
18.68%

5-Year Return

IGNE
99.83%
S&P 500
70.99%

Compare To: IGNE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IGNE

Valuation Measures

As of 4/19/2024
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    228.10

  • Enterprise Value/EBITDA

    -2.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -8.21%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    4.8k

  • Net Income Avi to Common (ttm)

    -2.37M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    269.29k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -442.78k

People Also Watch